Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan
ConclusionsThe safety and efficacy profiles in this postmarketing observational study were consistent with prior data and registration clinical trials. No new safety signals were observed while treating patients with metastatic soft tissue sarcoma with pazopanib.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Hypertension | Japan Health | Sarcomas | Soft Tissue Sarcoma | Study